ISSN 2736-1594
International Journal of Obstetrics and Gynecology ISSN 2326-7234 Vol. 7 (10), pp. 001-003, October, 2019. © International Scholars Journals
Short Communication
A comparative study on ofloxacin and azithromycin in combination with metronidazole to outpatients with pelvic inflammatory disease
Fariba Mirblook1, Maryam Asgharnia1, Kambiz Forghanparast2 and Mitra Ahmad Soltani1*
1Department of Obstetrics and Gynecology, Alzahra Hospital, Guilan university of Medical Sciences, Namjo street Rasht, Guilan , Iran.
2Faculty of Medicine, Guilan university of Medical Sciences , Rasht, Guilan , Iran.
Accepted 09 April, 2019
Abstract
This study aims to compare two oral treatments: Ofloxacin and Metronidazole, with Azithromycin and Metronidazole in outpatients with Pelvic Inflammatory Disease. This study was carried out by Randomized Clinical Trial in Al-zahra Women Hospital of Rasht. Two hundred women were selected based on eligibility criteria of having three out of the five following symptoms: lower abdominal pain, vaginal discharge, adnexal tenderness, cervical motion tenderness and cervisitis. Two hundred patients were divided randomly into two groups (A and B). Group A was treated with Ofloxacin (400 mg) with Metronidazole (500 mg) and Group B was treated with a single dose of oral Azithromycin (1gr) with Metronidazole (500 mg) for 10 days. These two regimens were compared in terms of side effects and efficacy. Patients were revisited 14 days after the beginning of the treatment by a physician. The continuation of even one clinical symptom was considered as treatment failure. The study was completed in a six month period. Two hundred patients were assigned into two groups of 100 patients per group and treated with medication regimens A or B. Eleven patients were excluded from the study (adverse drug reaction no=4, no return visit no=5, and lack of compliance with treatments no=2). Pre-treatment symptoms for the groups were not significantly different except CMT (P=0.015). Post-treatment cure rates for the two groups were 90.3% for group A and 93.75% for group B (p=0.383). There was no statistical difference in the outcome of treatments. GI upset in four patients in Met with Ofl, and three patients in Met with Azi group resulted in discontinuation of their treatment (р=0.206). Azithromycin was the preferred treatment for Pelvic Inflammatory Disease because of the simplicity and shorter duration of its use.
Key words: Pelvic inflammatory disease, ofloxacin, azithromycin, metronidazole.